KIT D820E

CI-VAR-00000564Explore in graph →CIViC 2736

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Thymus Carcinoma1
KIT D820E	Sorafenib	Predictive	C	Supports Sensitivity Response	3	submitted	EID7356 Heavily pretreated patient with advanced thymic carcinoma was responsive to multikinases inhibitor BAY 43-9006 (Sorafenib). and carried a c-kit missense mutation on exon 17 (D820E). PMID 19461405 · Bisagni et al., 2009 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.